Professor Stephen Nicholls
Disclosure details
S.J.N. has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx and Sanofi-Regeneron and is also a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi- Regeneron, Vaxxinity, CSL Sequiris, and Novo Nordisk.Director of Victorian Heart Hospital, MonashHeart & ICU, Monash Health
Director of Victorian Heart Institute, Monash University
Professor of Cardiology, Monash University, Clayton, Australia
Professor Steve Nicholls is the inaugural Director of the Victorian Heart Institute and a Professor of Cardiology at Monash University. He is the inaugural Director of the Victorian Heart Hospital which opened in February 2023.
Steve is a preventive cardiologist. His clinical interest is focused on identifying those at risk of heart disease earlier, and more effectively, and preventing catastrophic cardiovascular events from occurring. He is committed to solutions which improve equity across risk and management, focusing on women’s heart health and other under-served populations.
His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large-scale clinical trials of new therapies designed to reduce the risk of heart disease.
He is Chair of the Asia Pacific Cardiometabolic Consortium, President of the Cardiac Society of Australia and New Zealand and a Fellow of the Australian Academy of Health and Medical Sciences.
